Search
MSK head and neck surgeons are investigating novel imaging methods that enable them to detect and visualize cancer cells during an operation.
Find out what it’s like to undergo cancer treatment when you work at a cancer hospital like Memorial Sloan Kettering.
Following surgery to remove NF2 tumors in her brain, MSK patient Maggie Chess developed a sudden passion and talent for abstract painting, a rare outcome that has transformed her life.
Saad Usmani, MD, has been named Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center.
Along with Valentine's Day, February marks American Heart Month. MSK’s Vice Chair of Radiation Oncology, Dr Oren Cahlon talks on how his team are making radiation-induced heart disease “a thing of the past” for our breast cancer patients.
Learn about some of the latest treatments for thyroid cancer and clinical trials that have been led by researchers from MSK.
In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.
The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
With notable cases of pancreatic cancer in the news this year, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the disease and sharing some of the encouraging breakthroughs in research and treatment.